founder, CEO & President
Jacob Glanville is an Entrepreneur and Computational Immuno-Engineer. As Founder, CEO and President of Centivax, he enjoys collaborating with multiple partners to generate exciting new technologies in biomedicine.
Ceo & president
Dr. Aoife Brennan is Synlogic’s President and CEO. She is an experienced physician scientist and drug developer responsible for the successful development and registration of multiple transformative medicines. Prior, she was Biogen’s VP and Head of the Rare Disease Innovation Unit.
Karl is a seasoned venture capitalist in early-stage biotech. He has been working with Steve Blank, the guru of “Lean Launch”, to apply his methods to biotech startups. He also founded Codon Capital to focus on early-stage therapeutics, research tools, and synthetic biology.
AbCellera Biologics, Inc.
Dr. Falconer is responsible for AbCellera’s long-term strategy for expanding its technology stack, which searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease.
Co-founder & CTO
Co-founder and CTO of Mammoth Biosciences, a startup developing the CRISPR platform for diagnostics and therapeutics. She received her Ph.D. from UC Berkeley, was a Forbes 30 U 30, Endpoint’s Top 20 Women in Biopharma, and gave a TEDx talk on the potential for CRISPR to democratize diagnostics.
Co-Founder, CEO, & PResident
Scribe Therapeutics, Inc.
Benjamin Oakes PhD is co-Founder and CEO of California-based gene-editing company Scribe Therapeutics, a spin-out from Nobel Laureate Jennifer Doudna's lab at University of California Berkeley. Ben received a Ph.D. in Molecular and Cellular Biology from UC Berkeley.
Laura Sepp-Lorenzino, Ph.D. is the CSO at Intellia Therapeutics and a recognized expert on nucleic acid therapies R+D. She held leadership positions at Vertex, Alnylam and Merck, serves in several SABs and is a BOD member for Taysha Gene Therapies
Senior Advisor & Executive Coach
Mickey is a pioneer in pervasive computing, collaborative human/machine innovation, human-centered design, and education. He is a founding member of BCG's Deep Tech Mission for Good that focuses on Codesign along with Nature to tackle major societal challenges.
Co-founder & CSO
As the Co-founder & CSO of Octarine, Nick's scientific career spans academia & industry with a core focus on yeast metabolic engineering & fermentation which is being used at Octarine to develop biosynthetic processes for natural & novel cannabinoid & psychedelic molecules.
Mr. Solomon was the co-founder and CEO of ProClara (formerly NeuroPhage), which is pioneering an approach to treating neurodegenerative diseases. Under his leadership, the company raised more than $100 million. He holds an M.B.A. with honors from the Harvard Business School.
VP Microbiology & Automation
I leverage my expertise in fungal microbiology, molecular genetics, transcriptomics, high throughput comparative genomics, evolutionary biology and synthetic biology to crack the code of therapeutically relevant natural products encoded in fungal genomes.
Lead Scientist & Head of Application Science
Inventia Life Science Pty Ltd
Dr Martin Engel is the Lead Scientist at Inventia Life Science, driving the development of hydrogel 3D cell cultures and organoid models. Dr Engel has extensive experience in developing and using 3D cultures, including stem-cell derived organoids.
Karen Tkach Tuzman
Karen guides BioCentury’s coverage of emerging biology and technologies. She has written extensively about synthetic biology and data science, covering innovation in industry and academia, and dissecting trends in company formation and investments.
Co-founder & CEO
Adaptive Phage Therapeutics
Greg Merril is co-founder & CEO of Adaptive Phage Therapeutics. APT is a clinical-stage biotech advancing phage therapy for drug resistant infections. He served as Chair of several international phage therapy conferences.
Co-founder & CSO
Kristy has nearly 20 years of experience engineering microbial hosts for the production of small molecules. Prior to co-founding Antheia in 2015, she earned her Ph.D. in Chemical Engineering at Caltech and worked as a scientist at Amyris and Lygos.
Dr. Eric D. Hobbs is CEO of Berkeley Lights. He is an inventor & Mechanical Design PhD passionate about transforming concepts into product, operations, structured problem solving, precision engineering, MEMS, intellectual property, & system-level design.